New study proves efficacy of the ADVOS system in the treatment of COVID-19

The ADVOS system from EIT Health Catapult Finalist 2019, ADVITOS, enables simultaneous treatment in multi-organ failure. A new study by the Klinikum rechts der Isar proves that the system is also highly effective in the treatment of COVID-19 patients.


With the ADVOS multi-organ device (ADVanced Organ Support) developed by ADVITOS, a holistic way to treat all three detoxification organs — liver, lungs and kidneys — simultaneously is made possible. The Munich-based start-up is thus revolutionising the treatment of multi-organ failure, which previously required the use of various supportive extracorporeal procedures, such as mechanical ventilation, ECMO (extracorporeal membrane oxygenation), dialysis and liver supportive therapy. ADVOS eliminates water-soluble toxins (kidney), protein-bound toxins (liver and kidney) and CO2 (lung) and corrects acid-base imbalances in the blood. The therapy’s far-reaching efficacy, which significantly increases the chances of survival for patients with severe organ failure, propelled the ADVITOS team to the finals of the EIT Health CATAPULT programme in 2019. The ADVOS therapy is now CE-marked, is used in intensive care units of 20 leading hospitals in Germany and is on its way to the international market.

A new study by the II Medical Clinic of the Klinikum rechts der Isar of the Technical University of Munich, recently published in the International Journal of Artificial Organs, now proves that ADVOS therapy can also achieve decisive success in the treatment of COVID-19 patients. The study investigated to what extent the therapy is suitable for treating COVID-19. The researchers found that patients in advanced stages of the disease can benefit from the device.

Multi-organ failure massively increases the mortality of COVID-19 patients. This is due to the imbalance of the acid-base balance that can occur when the three main detoxification organs — liver, lungs and kidneys — are impaired. This imbalance is exacerbated when the patient develops problems with carbon dioxide removal as a result of severe respiratory insufficiency. The study set out to evaluate the ADVOS system as a treatment option for COVID-19 patients with multi-organ failure and carbon dioxide removal problems. The system’s less invasive approach combines extracorporeal CO2 removal and multiple organ support for the liver and kidneys in a single haemodialysis machine.

To test the efficacy of the 4-in-1 treatment system, the researchers involved COVID-19 patients with severe respiratory failure in the study who had received at least two treatments with the ADVOS multisystem. It was observed that the acid-base balance of the patients corrected rapidly during the ADVOS treatments. Carbon dioxide removal was also shown to be improved by the continuous treatment and the PaCO2 value was significantly reduced.

From these observations, the researchers concluded that the use of the ADVOS multisystem can have a positive impact on the treatment of patients with severe course of COVID-19. The study was able to clearly observe that the system contributes to the normalisation of the acid-base balance, among other things by effectively supporting CO2 removal.